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Abstract: Metal toxicity has been identified as a possible risk factor for amyotrophic lateral sclerosis (ALS) and other 
neurodegenerative disorders. We conducted a retrospective chart review of urinary, hair and blood metal levels and serum 
ferritin in 321 people with ALS seen over a ten-year period at the Massachusetts General Hospital (MGH). We found that 
hair lead levels and serum ferritin levels were elevated in ALS patients compared to published normal values. Metal levels 
of arsenic, lead, mercury, cadmium, thallium, cobalt and aluminum in 24-hour urine specimens and lead, mercury and ar-
senic in serum were within the normal range. We conclude that twenty-four hour urine or blood testing for metals is not 
warranted as part of the evaluation of ALS. Elevated levels of serum ferritin in ALS population could reflect an underly-
ing perturbation in iron metabolism. 
INTRODUCTION 
  Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disorder that affects predominantly motor neu-
rons. The cause of the sporadic form of ALS is unknown [1, 
2]; metal toxicity has been proposed as a possible risk factor 
[3, 4]. Several approaches have been taken to investigate 
metal toxicity in ALS, including: measuring metal levels in 
body tissues and fluids; comparing case-control cohorts to 
establish the risk of contracting ALS from metal exposure; 
and evaluating case reports of clinical syndromes resembling 
ALS that developed following metal exposure. The possibil-
ity that people with ALS might have a genetic susceptibility 
to the effects of metals has also been studied [5]. Serum fer-
ritin levels reflect both inflammation and iron imbalance in 
defined pathophysiological conditions such as hemochroma-
tosis (iron) and the anemia of chronic disease (inflammation) 
[6-8]. We conducted a retrospective analysis of measure-
ments of metals in urine, blood and hair samples and tested 
serum ferritin levels in ALS compared to age matched sub-
jects. 
METHODS 
  A retrospective chart review of 321 people with ALS 
seen at the Neuromuscular Clinic at the Massachusetts Gen-
eral Hospital (MGH) between January 1994 and December 
2003 was performed. Approval for the chart review was ob-
tained from the MGH Institutional Review Board. Partici-
pants were selected if they were evaluated for at least one 
laboratory test related to metal level in serum, hair or urine. 
All participants were identified using the computerized 
MGH Research Patient Data Registry (RPDR) and each par-
ticipant’s diagnosis was confirmed according to the El-
Escorial criteria [9]. Participant’s gender, date of birth, site 
and date of symptom onset and date of diagnosis were   
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recorded. The participants were selected randomly based on 
availability of outpatient medical records. All patients whose 
complete medical record file was maintained at the Outpa-
tient Clinic were included in the chart review. The laboratory 
samples collected from the patients were analyzed at the 
Nichols Institute in Chantilly, Virginia. Normal reference 
ranges for metals were available and had been obtained from 
published data and private internal testing of healthy volun-
teers at the Nichols Institute [10-12].  
  After the initial chart review, additional stored serum 
samples from 30 participants with ALS and 30 healthy con-
trol volunteers who participated in an ALS observational 
study from 1998 to 2002 [13] were analyzed for ferritin lev-
els. These samples were sent to the Pathology Laboratory at 
MGH and analyzed using an electrochemiluminescent im-
munoassay, ELECSYS 2010 (Roche Diagnostics, Indianapo-
lis, IN).  
  Statistical analyses were performed using SAS version 
8.0 (Cary, NC), and a univariate analysis were used to ana-
lyze the data. Student’s T-test was used to compare ferritin 
levels between ALS patients and controls.  
RESULTS 
  The majority of participants were male (59%) and the 
mean age at symptom onset was 56.3 years (± 13.0 SD). The 
number of participants who underwent each laboratory test 
and the normal reference ranges are provided in Table 1. The 
mean 24-hour urine levels of arsenic, lead, mercury, cad-
mium, thallium, cobalt and aluminum were within the nor-
mal range (Table 1). Four participants had lead levels meas-
ured from hair. The average hair lead level was elevated (1.9 
ug/gm ± 2.6 SD; normal range = 0 - 0.99 ug/gm). Serum 
ferritin levels were measured in 12 participants (six male and 
six females). The mean serum ferritin level was elevated in 
the participants with ALS. In males with ALS, the average 
ferritin level was 668 ng/ml (± 785.1 SD) compared to a 
normal range of 22 - 322 ng/ml. In female ALS patients, the 52    The Open Neurology Journal, 2008, Volume 2  Qureshi et al. 
average ferritin level was 237.2 ng/ml (± 180.3 SD; normal 
range 10 - 291 ng/ml).  
  Based on these results we conducted additional analysis 
of serum ferritin levels in 30 individuals with ALS and 30 
healthy controls. Compared with the healthy controls, the 
mean serum ferritin level in the ALS population was higher 
(ANOVA: males p=0.037, females p=0.032). The mean se-
rum ferritin level in the 17 males with ALS was 269.9 ng/ml 
(± 126.4 SD), compared to 164.1 ng/ml (± 142.2 SD) in 14 
healthy controls. The mean serum ferritin value in 13 fe-
males with ALS was 183.5 ng/ml (± 186.9 SD) compared to 
71.3 ng/ml (± 60.4 SD) in 16 female control subjects (Figs. 1 
and 2). 
DISCUSSION 
  In a chart review of patients with ALS seen at MGH over 
a 10-year period we did not find evidence of increased metal 
levels in urine or blood compared to healthy controls. The 
hair lead levels were elevated in a limited number of partici-
pants who had this test performed. We also found signifi-
cantly increased serum ferritin levels in both males and fe-
males with ALS. We confirmed this finding by measuring 
ferritin assays in a small set of stored serum samples. 
  Metal concentrations in blood and urine reflect recent 
exposures [14]; therefore measurements of metal levels in 
these tissues may not be useful except in clinical situations 
where a differential diagnosis between acute metal poisoning 
and a motor neuron disease is needed. The half-life of most 
metals in blood is usually measured in weeks [15]. By con-
trast, analysis of the metal content of hair is useful in assess-
ing variations in long-term exposure to metals [16], espe-
cially vanadium [17], arsenic [18] and mercury [19]. How-
Table 1.  Metal Levels in Blood, Hair and 24-Hour Urine Samples  
Laboratory Investigation  Number of ALS Subjects  Mean Level--ALS Subjects (units)  Standard Deviation (SD)  Normal Range 
Urine         
 Arsenic  110  52.3 (mcg/L)  66.1  0 – 80 mcg/L 
 Lead  110  13.7 (mcg/L)  10.9  0 – 50 mcg/L 
 Mercury  112  8.9 (mcg/L)  2.7  0 – 20 mcg/L 
 Cadmium  98  0.9 (mcg/L)  2.9  0 – 3 mcg/L 
 Thallium  79  0.9 (mcg/L)  1.8  0 – 2 mcg/L 
 Cobalt  70  0.5 (mcg/L)  0.1  0 – 2 mcg/L 
 Aluminum  8  12.9 (mcg/24 hr)  8.9  7 – 40 mcg/24 hr 
Serum         
 Lead  86  4.2 (mcg/dL)  2.9  0 – 25 mcg/dL 
 Arsenic   6  10 (mcg/L)  0  0 – 60 mcg/L 
 Mercury  6  15.2 (ug/L)  6.4  0 – 50 ug/L 
Hair         
 Lead  4  1.9 (ug/GM)  2.6  0 – 0.99 ug/GM 
 Arsenic   5  0.2 (ug/GM)  0.4  0 – 0.9 ug/GM 
 Mercury   5  1.7 (ug/GM)  1.1  0 – 24.9 ug/GM 
Serum Ferritin          
 Male  6  668.0 (ng/mL)  785.1 22-322  ng/mL 
 Female  6  237.2 (ng/mL)  180.3 10-291  ng/mL 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The mean serum ferritin level in 17 male participants with 
ALS (269.9 ng/ml ± 126.4 SD) and 14 healthy controls (164.1 
ng/ml ± 142.2 SD) is depicted in boxplot. The horizontal line re-
flects the median and the box provides the interquartile range from 
the 25
th to 75
th percentile. Dots represent the observations outside 
of 10th and 90th percentiles. Serum Ferritin and Metal Levels as Risk Factors  The Open Neurology Journal, 2008, Volume 2    53 
ever, several factors influence metal levels found in hair 
[20], and there is strong evidence of disparities between 
laboratories in hair metal measurements that cannot be at-
tributed to the quality of laboratory methods [21, 22]. A re-
cent study of hair metal levels in an ALS population found 
lower vanadium and manganese levels [17] but concluded 
that hair samples do not reflect exposures that may have oc-
curred prior to the period in which the hair was growing. 
Chronic metal exposure can also be measured in bone. Since 
metals like lead and aluminum accumulate in the bones over 
the course of a lifetime, bone may be an endogenous source 
of these metals in the body [23]. The half-life of lead in the 
patella is three to five months, but in the tibia it is 15 to 25 
years [15, 24]. Direct measurement of lead levels in bone 
provides data on cumulative past exposure that can be used 
in epidemiological analysis and clinical assessment [25].  
  The finding that hair lead levels were elevated in our 
cohort supports the earlier published data that demonstrated 
chronic elevation of bone lead in patients with ALS [24]. It 
has been shown that metals like zinc and cadmium regulate 
translation of ferritin by modulating binding of Iron-
regulatory protein 1 (IRP1) to the Iron-regulatory element 
(IRE) in the 5’UTR of the ferritin mRNA [26]. It is possible 
that lead acts in a similar pathway to impact the synthesis of 
ferritin.  
  Elevated serum ferritin is an indicator of hemachromato-
sis and inflammatory stress [27]. The increased serum fer-
ritin levels, as seen during inflammation [28], are induced by 
stress-induced factors such as interleukin-1 (IL-1) [29, 30]. 
Ferritin binds to iron and is involved in detoxifying iron and 
other trivalent trace metals in the brain [31]. In a transgenic 
mutation superoxide dismutase (SOD1) mouse model of 
motor neuron disease, neural ferritin expression was in-
creased as a response to increased oxidative stress [32]. De-
fects in ferritin metabolism are possibly involved in etiology 
of other neurodegenerative deficits, including Friedrich 
ataxia [33], Parkinson’s disease [34], and Alzheimer disease 
[35]. Despite several reports of altered iron metabolism [36] 
and increased total brain ferritin in individuals with Alz-
heimer disease [37], their serum ferritin levels remain within 
the normal range [38].  
  Another crucial question concerns the potential role in 
ALS of polymorphisms in the hemachromatosis gene (HFE), 
located on the short arm of chromosome 6 at location 6p21.3 
[39]. Two mutations in the HFE gene, H63D and C282Y, 
have been reported to increase susceptibility to ALS [40-42]. 
The HFE protein affects iron metabolism by binding to the 
transferrin receptor and reducing its affinity for iron-binding 
transferrin.  However,  the    HFE allele can independently 
increase neuronal oxidative stress levels without necessarily 
affecting iron load [39]. The altered activity of SOD1 (either 
wild-type or the mutant SOD1G93A) modulates the levels of 
ferritin as well as transferrin receptor [43]. In light of these 
findings it will be important to further study the role of fer-
ritin in in vitro and in vivo models of SOD1 toxicity. 
  The finding of elevated serum ferritin in a large sample 
of ALS population may simply be an acute phase reactant, 
rather than a specific maker of iron metabolism dysregula-
tion. The role of ferritin in ALS needs to be studied in a lon-
gitudinal cohort and its relationship with survival and meas-
ures of disease progression should be explored. We conclude 
that further study of the role of ferritin and other proteins 
involved in iron metabolism is warranted in the ALS popula-
tion, particularly in relation to genetic polymorphisms that 
affect cellular oxidative stress levels. 
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